Rob Bohacs, Pharmatech’s CEO, said, "The world of cancer clinical trials is going through a complete transformation with highly targeted biomarker clinical trials, and the work of the current clinical trial management process isn't configured to accommodate these types of 'next generation' clinical trials, which will ultimately drive the prescription cancer drugs of tomorrow."
Bohacs said, "Pharmaceutical companies are feeling the pressure of the challenges associated with highly-targeted drugs and the magnificent cost associated with the old-generation management of these types of clinical trials. We can reduce the time of managing trials by half if we just focus on a more efficient process, ultimately significantly improving the experience for patients and researchers."
While Pharmatech has been around for nearly 20 years as a service provider to pharmaceutical companies, in the last two years the company has completely reinvented itself into a full-fledged genomics and technology company. The company can integrate patient medical records with the genetic information from a patient's tumor to identify the right clinical trial for the patient.